deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT01336920

Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

Phase I Study of Carfilzomib for the Treatment of T-Cell Lymphoma

Sponsor: Amgen

Conditions Adult Nasal Type Extranodal NK/T-cell Lymphoma Anaplastic Large Cell Lymphoma Angioimmunoblastic T-cell Lymphoma Peripheral T-cell Lymphoma Recurrent Adult T-cell Leukemia/Lymphoma
Interventions carfilzomib
Updated 9 times since 2017 Last updated: Sep 13, 2023 Started: Jun 21, 2011 Primary completion: Apr 1, 2015 Completion: Mar 1, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Adult Nasal Type Extranodal NK/T-cell Lymphoma and Anaplastic Large Cell Lymphoma and is currently completed. Amgen leads this study, which shows 9 recorded versions since 2011 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshotActive Not Recruiting~Jun 2017 – ~Jun 2018 · 12 months · monthly snapshotActive Not Recruiting~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshotActive Not Recruiting~Aug 2018 – ~Jan 2021 · 29 months · monthly snapshotCompleted~Jan 2021 – ~Oct 2023 · 33 months · monthly snapshotCompleted~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Oct 2023 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — Oct 2023 [monthly]

    Completed PHASE1

  5. Aug 2018 — Jan 2021 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

▶ Show 4 earlier versions

  1. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE1

  2. Jun 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

  3. Feb 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE1

  4. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1

    First recorded

Jun 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Amgen
  • National Cancer Institute (NCI)
  • University of Nebraska
Data source: University of Nebraska

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations